---
title: "Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292284865.md"
description: "Halozyme Therapeutics' average 12-month price target was lowered to $83.44 by nine analysts, down from $83.90, implying a 6% upside based on the July 9 closing price. Despite the cut, the consensus rating remains 'Buy' among 11 covering analysts, with forecasts ranging from $57 to $96 per share."
datetime: "2026-07-10T07:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292284865.md)
  - [en](https://longbridge.com/en/news/292284865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292284865.md)
---

# Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside

-   According to estimates from 9 analysts, Halozyme Therapeutics, Inc. stock's average price target has fallen from $83.9 to $83.44, with forecasts ranging from $57 to $96 per share
-   Based on the Jul. 9 closing price, the updated target implies approximately 6% potential upside
-   Consensus rating remains at “Buy” across 11 covering analysts, with 7 Buys, 3 Holds and 1 Sells

Explore more price target data and ratings for Halozyme Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Halozyme Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)
- [Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock](https://longbridge.com/en/news/295589663.md)
- [Halozyme director Bernadette Connaughton disposes of 1.626 shares worth $167.152,8](https://longbridge.com/en/news/295584667.md)
- [Empowered Funds LLC Reduces Position in Restaurant Brands International Inc. $QSR](https://longbridge.com/en/news/296191912.md)
- [LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/296003421.md)